Literature DB >> 21727051

Therapeutic drug monitoring of tacrolimus by liquid chromatography-tandem mass spectrometry: is it truly a routine test?

Paul J Taylor1, Michael E Franklin, Chun-Hui Tai, Peter I Pillans.   

Abstract

Therapeutic drug monitoring of tacrolimus by high-performance liquid chromatography-tandem mass spectrometry has become standard practice. We report on the long-term (4.5 years) use of one such method. Whole blood samples (25 μL) were treated with zinc sulphate (100 μL) and acetonitrile containing ascomycin (internal standard, 250 μL). A high-performance liquid chromatography-tandem mass spectrometer operating in positive ion mode with an electrospray interface was used. Chromatography was performed on a TDM C(18) cartridge column (10 mm × 2.1 mm, 10 μm, Waters) using a switch gradient. A total of 4029 batches were analyzed for tacrolimus; this comprised of 81950 analyses of which 61027 were patient samples. Calibration curves (1.0-50 μg/L) were run on 1765 occasions (mean r(2)=0.999; range r(2)=0.988-0.999). Inter-batch accuracy and imprecision of the method (2.5, 12.5 and 30.0 μg/L), when in routine use, was 97.6-98.5% and <8.0%, respectively (n=4031). Evaluation of the method against other methods in an external quality control scheme revealed good agreement by linear regression analysis (y=0.924x+0.196, r(2)=0.985). The percentage difference between our results and that of all methods revealed a mean bias of -6.3% and a range of -33.3% to 11.1%. During the evaluation period, four batch failures occurred (0.1% failure rate) and greater than 1000 samples per analytical column was achieved. In conclusion, the described method is ideally suited as a routine test for tacrolimus in the clinical setting.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21727051     DOI: 10.1016/j.jchromb.2011.06.024

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

Review 1.  Usage and limitations of liquid chromatography-tandem mass spectrometry (LC-MS/MS) in clinical routine laboratories.

Authors:  Christoph Seger
Journal:  Wien Med Wochenschr       Date:  2012-11-06

2.  Analysis of tacrolimus and creatinine from a single dried blood spot using liquid chromatography tandem mass spectrometry.

Authors:  Dennis R Koop; Lisa A Bleyle; Myrna Munar; Ganesh Cherala; Amira Al-Uzri
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-03-04       Impact factor: 3.205

Review 3.  Review of Chromatographic Methods Coupled with Modern Detection Techniques Applied in the Therapeutic Drugs Monitoring (TDM).

Authors:  Tomasz Tuzimski; Anna Petruczynik
Journal:  Molecules       Date:  2020-09-03       Impact factor: 4.411

4.  Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling.

Authors:  Elisabet Størset; Nick Holford; Stefanie Hennig; Troels K Bergmann; Stein Bergan; Sara Bremer; Anders Åsberg; Karsten Midtvedt; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

5.  Tacrolimus Toxicity due to Biliary Obstruction in a Combined Kidney and Liver Transplant Recipient.

Authors:  Samuel Chan; Michael T Burke; David W Johnson; Ross S Francis; David W Mudge
Journal:  Case Rep Transplant       Date:  2017-01-09

6.  Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients.

Authors:  Marith I Francke; Dennis A Hesselink; Yi Li; Birgit C P Koch; Lucia E A de Wit; Ron H N van Schaik; Lin Yang; Carla C Baan; Teun van Gelder; Brenda C M de Winter
Journal:  Br J Clin Pharmacol       Date:  2020-11-24       Impact factor: 4.335

7.  Development and Validation of the New Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Unbound Tacrolimus in the Plasma Ultrafiltrate of Transplant Recipients.

Authors:  Magdalena Bodnar-Broniarczyk; Karola Warzyszyńska; Katarzyna Czerwińska; Dorota Marszałek; Natalia Dziewa; Maciej Kosieradzki; Tomasz Pawiński
Journal:  Pharmaceutics       Date:  2022-03-12       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.